<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250405</url>
  </required_header>
  <id_info>
    <org_study_id>CA2009-0008</org_study_id>
    <nct_id>NCT01250405</nct_id>
  </id_info>
  <brief_title>Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients</brief_title>
  <acronym>ECIRA</acronym>
  <official_title>Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether reduction of serum calcium concentration by
      cinacalcet leads to reduction of mean blood pressure adjusted c-fPWV. The secondary
      objectives are to study the effects of calcium reduction on 1) carotid-radial PWV (c-rPWV),
      2) common carotid artery (CCA) biomechanics, 3) pulse wave profile and cardiac function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Arterial stiffness with be measured after 1 week with placebo and after 1 week with cinacalcet</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventricular function</measure>
    <time_frame>Ventricular function with be measured after 1 week with placebo and after 1 week with cinacalcet</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Cinacalcet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet</intervention_name>
    <description>One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days</description>
    <arm_group_label>Cinacalcet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic (&gt; 3 months) hemodialysis population of &gt; 18 years old

          -  PTH &gt; 300 ng/L

          -  corrected Ca &gt; 2.10 mmol/L

          -  stable hypertensive drugs (&gt; 1 month)

          -  stable doses of phosphate binders and dialysis calcium concentration

          -  palpable femoral pulse

          -  systolic BP of 90-180 mmHg

          -  expected survival of &gt; 6 months

        Exclusion Criteria:

          -  hemodialysis &gt; 3 years

          -  acute infection

          -  history of myocardial infarction or stroke within the past 3 months

          -  inability to consent

          -  intolerance to cinacalcet

          -  inadequate birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen Agharazii, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karine Marquis</name>
      <address>
        <city>Qu√©bec</city>
        <state>Quebec</state>
        <zip>G1R2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Karine Marquis</investigator_full_name>
    <investigator_title>Professionnelle de recherche</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

